- Home
- GOSS vs CHPT Comparison
GOSS vs CHPT Comparison
Compare GOSS & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- CHPT
- Stock Information
- Founded
- GOSS 2015
- CHPT 2007
- Country
- GOSS United States
- CHPT United States
- Employees
- GOSS N/A
- CHPT N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- CHPT Industrial Specialties
- Sector
- GOSS Health Care
- CHPT Consumer Discretionary
- Exchange
- GOSS Nasdaq
- CHPT Nasdaq
- Market Cap
- GOSS 347.8M
- CHPT 340.1M
- IPO Year
- GOSS 2019
- CHPT N/A
- Fundamental
- Price
- GOSS $2.47
- CHPT $11.29
- Analyst Decision
- GOSS Strong Buy
- CHPT Hold
- Analyst Count
- GOSS 4
- CHPT 10
- Target Price
- GOSS $8.50
- CHPT $29.13
- AVG Volume (30 Days)
- GOSS 3.1M
- CHPT 532.9K
- Earning Date
- GOSS 08-05-2025
- CHPT 09-03-2025
- Dividend Yield
- GOSS N/A
- CHPT N/A
- EPS Growth
- GOSS N/A
- CHPT N/A
- EPS
- GOSS N/A
- CHPT N/A
- Revenue
- GOSS $40,237,000.00
- CHPT $407,681,000.00
- Revenue This Year
- GOSS N/A
- CHPT $2.79
- Revenue Next Year
- GOSS $30.65
- CHPT $24.20
- P/E Ratio
- GOSS N/A
- CHPT N/A
- Revenue Growth
- GOSS N/A
- CHPT N/A
- 52 Week Low
- GOSS $0.66
- CHPT $8.55
- 52 Week High
- GOSS $2.65
- CHPT $39.20
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- CHPT 47.09
- Support Level
- GOSS $2.38
- CHPT $11.41
- Resistance Level
- GOSS $2.65
- CHPT $11.85
- Average True Range (ATR)
- GOSS 0.15
- CHPT 0.59
- MACD
- GOSS 0.03
- CHPT 0.08
- Stochastic Oscillator
- GOSS 76.67
- CHPT 39.55
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.